[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# $arwrs

$ARWR's REDEMPLO receives FDA approval for clinically diagnosed FCS, not just genetically confirmed cases, expanding its potential patient base. The drug is priced at $60K, positioning it to compete with $IONS Tryngolza.

### About $arwrs
$ARWR is a cryptocurrency project focused on decentralized finance.  

### Insights
- $arwrs mentions hit X which is XXX% higher than it's daily average.
- $arwrs engagements hit 2179 which is XXX% higher than it's daily average.
- $arwrs creators hit X which is XXX% higher than it's daily average.
- $arwrs engagements is up 1089.63% from the previous month.
- $arwrs Creators hit a 52-Week high of X for the day
- $arwrs Creators hit an all time of X for the day
- $arwrs Mentions hit a 52-Week high of X for the day
- $arwrs Mentions hit an all time of X for the day

### Engagements: XXXXX (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$arwrs/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$arwrs/time-series/interactions.tsv)  
Current Value: XXXXX  
Daily Average: XXX  
X Week: XXXXX +129%  
X Month: XXXXXX +1,090%  
X Months: XXXXXX +163%  
X Year: XXXXXX +85%  
1-Year High: XXXXX on 2025-11-18  
1-Year Low: X on 2025-08-12  

Engagements by network (24h):
X: XXXXX

  
  
### Mentions: X (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$arwrs/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$arwrs/time-series/posts_active.tsv)  
Current Value: X  
Daily Average: X  
X Week: X -XX%  
X Month: XX +300%  
X Months: XX +82%  
X Year: XX +121%  
1-Year High: X on 2025-12-04  
1-Year Low: X on 2024-12-06  

Mentions by network (24h):
X: XX

  
  
### Creators: X (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$arwrs/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$arwrs/time-series/contributors_active.tsv)  
X unique social accounts have posts mentioning $arwrs in the last XX hours which is up XXX% from X in the previous XX hours
Daily Average: X  
X Week: X -XX%  
X Month: X +350%  
X Months: XX +56%  
X Year: XX +144%  
1-Year High: X on 2025-12-04  
1-Year Low: X on 2024-12-06  

The most influential creators that mention $arwrs in the last XX hours

| Creator                                      | Rank | Followers | Posts | Engagements |
| -------                                      | ---- | --------- | ----- | ----------- |
| [@BioBoyScout](/creator/twitter/BioBoyScout) | X    | XXXXX     | X     | XXX         |

[View More](/list/creators/$arwrs/100)
  
  
### Sentiment: XXX%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$arwrs/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$arwrs/time-series/sentiment.tsv)  

Most Supportive Themes:
- Pipeline and Trial Advancements: (40%) Posts highlight progress in clinical trials and pipeline development, suggesting future growth and innovation.
- Drug Efficacy and Innovation: (30%) Discussions focus on the potency and effectiveness of drugs like REDEMPLO, emphasizing scientific breakthroughs.
  
Most Critical Themes:
- Regulatory and Diagnostic Nuances: (30%) Clarifications on FDA approval for REDEMPLO highlight specific diagnostic criteria, which could impact broader adoption.
  

### Top $arwrs Social Posts
Top posts by engagements in the last XX hours

*Showing only X posts for non-authenticated requests. Use your API key in requests for full results.*

"H.C. Wainwright $ARWR's PT to $XX from $XX and reiterated at a Buy rating. $IONS $REGN ALNY NVS H.C. Wainwright said we view the newly approved REDEMPLO (plozasiran) label as best-in-class across safety convenience and intent-to-treat population breadth. We believe that the label supports an initial launch focused on the FCS rare indication while laying the strategic foundation for expansion into high-risk severe hypertriglyceridemia (sHTG) in 2027. Meanwhile top-line readouts from the sHTG Phase X trials SHASTA-3 SHASTA-4 and MUIR-3 remain on track for 3Q26 which management remains confident"  
[X Link](https://x.com/Quantumup1/status/1996204804981313869) [@Quantumup1](/creator/x/Quantumup1) 2025-12-03T13:08Z 3919 followers, 1877 engagements


"$ARWR - The ability to perceive value (where others dont) can make you some decent coin. Post below from 12/5/24. Follow @MarketTrendAdv for more Dynamic Trend Trading ideas. ALWAYS DYOR. #receipts $SRPT"  
[X Link](https://x.com/MarketTrendAdv/status/1994369128266629209) [@MarketTrendAdv](/creator/x/MarketTrendAdv) 2025-11-28T11:33Z 2122 followers, 1774 engagements


"$ARWR's pipeline is firing on all cylinders Dosed first patient in Phase X YOSEMITE for zodasiran in HoFH filed for ARO-DIMER-PA & ARO-MAPT trials. CNS penetration breakthrough could unlock Alzheimer's treatments. Bullish future #Pharma"  
[X Link](https://x.com/PriyRaval/status/1993713404671078705) [@PriyRaval](/creator/x/PriyRaval) 2025-11-26T16:08Z 1093 followers, XXX engagements


"$ARWRs Redemplo for FCAS priced at $60K is positioned to compete directly with $IONS Tryngolza. @YaronWerber says The bottom line is that they'll have similar potential labels with slight differences but they're probably going to contract very differently with payers. And maybe $ARWR because of their studies is going to contract for the higher risk big market whereas $IONS because their studies were broader will inevitably contract much more broadlyBut these are both great drugs and it should be a really big market. #BiotechHangout"  
[X Link](https://x.com/BiotechCH/status/1991930481550430491) [@BiotechCH](/creator/x/BiotechCH) 2025-11-21T18:03Z 15.4K followers, 1201 engagements